{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:51:35Z","timestamp":1787626295481,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejca.2017.10.029","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T11:30:47Z","timestamp":1511523047000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"special_numbering":"C","title":["Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients"],"prefix":"10.1016","volume":"88","author":[{"given":"S.","family":"Valpione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gremel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mundra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Middlehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Galvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Girotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Garner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dhomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.C.","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2017.10.029_bib1","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1373\/49.5.740","article-title":"Quantitative analysis of pleural fluid cell-free DNA as a tool for the classification of pleural effusions","volume":"49","author":"Chan","year":"2003","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.ejca.2017.10.029_bib2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1373\/49.4.678","article-title":"Serial analysis of fetal DNA concentrations in maternal plasma in late pregnancy","volume":"49","author":"Chan","year":"2003","journal-title":"Clin Chem"},{"issue":"119","key":"10.1016\/j.ejca.2017.10.029_bib3","doi-asserted-by":"crossref","DOI":"10.3791\/55049","article-title":"Cell-free DNA integrity analysis in urine samples","author":"Casadio","year":"2017","journal-title":"J Vis Exp"},{"issue":"3","key":"10.1016\/j.ejca.2017.10.029_bib4","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2017.10.029_bib5","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2017.10.029_bib6","first-page":"767","article-title":"Circulating DNA in higher organisms cancer detection brings back to life an ignored phenomenon","volume":"51","author":"Stroun","year":"2005","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"20","key":"10.1016\/j.ejca.2017.10.029_bib7","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2004.11.123","article-title":"Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy","volume":"22","author":"Gautschi","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.029_bib8","doi-asserted-by":"crossref","first-page":"643189","DOI":"10.1155\/2014\/643189","article-title":"The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels","volume":"2014","author":"McGuire","year":"2014","journal-title":"PPAR Res"},{"issue":"3","key":"10.1016\/j.ejca.2017.10.029_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/clinchem\/48.3.421","article-title":"Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation","volume":"48","author":"Lui","year":"2002","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.ejca.2017.10.029_bib10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/annonc\/mdw619","article-title":"Circulating Tumor Markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine","volume":"28","author":"Batth","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.10.029_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdv498","article-title":"A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers","volume":"27","author":"Li","year":"2016","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2017.10.029_bib12","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-17-0114","article-title":"Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions","volume":"23","author":"Nishino","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2017.10.029_bib13","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.10.029_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2017.10.029_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejca.2008.10.028","article-title":"Evaluation of lymph nodes with RECIST 1.1","volume":"45","author":"Schwartz","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2017.10.029_bib16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejca.2008.10.031","article-title":"Lessons learned from independent central review","volume":"45","author":"Ford","year":"2009","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2017.10.029_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","article-title":"Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma","volume":"6","author":"Girotti","year":"2016","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.ejca.2017.10.029_bib18","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/annonc\/mdw278","article-title":"Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA","volume":"27","author":"Gremel","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.10.029_bib19","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/annonc\/mdx212","article-title":"Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study","volume":"28","author":"Cabel","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.10.029_bib20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.10.029_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"36","key":"10.1016\/j.ejca.2017.10.029_bib22","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T18:49:58Z","timestamp":1603392598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917313692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":22,"alternative-id":["S0959804917313692"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}